CD43/Sialophorin Antibody (SPM503), Novus Biologicals™

CD43/Sialophorin

Western Blot 0.5-1ug/ml, Flow Cytometry 0.5-1ug/million cells, Immunocytochemistry/Immunofluorescence 1-2ug/ml, Immunoprecipitation 0.5-1ug/500ug protein lysate, Immunohistochemistry-Paraffin 0.5-1.0ug/ml, Immunohistochemistry-Frozen 0.5-1.0ug/ml

Monoclonal

Purified

RUO

Human

P16150

6693

Myeloblastic KG1 cells

Primary

Store at 4C.

SPM503

Western Blot, Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunoprecipitation, Immunohistochemistry (Paraffin)

Unconjugated

Mouse

Immunology

PBS with 0.05% BSA. with 0.05% Sodium Azide

CD43 antigen, CD43), Galactoglycoprotein, GALGP, Leukocyte sialoglycoprotein, Sialophorin, sialophorin (gpL115, leukosialin, CD43)

SPN

IgG1 κ

Protein A purified

It recognizes a cell surface glycoprotein of 95/115/135kDa (depending upon the extent of glycosylation), identified as CD43. 70-90% of T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma.